Table 2.

Frequencies of KIR and KIR ligands in controls and cancer patients

ControlMelanomaBladderOvarian
KIR genes(n = 621)(n = 80)(n = 80)(n = 89)
 KIR2DL1606 (97.6%)79 (98.8%)75 (93.8%)86 (96.6%)
 KIR2DL2369 (59.4%)46 (57.5%)51 (63.8%)50 (56.2%)
 KIR2DL3558 (89.9%)75 (93.8%)66 (82.5%)80 (89.9%)
 KIR2DL5322 (51.9%)46 (57.5%)53 (66.3%)a47 (55.7%)
 KIR3DL1589 (94.8%)77 (96.3%)76 (95.0%)83 (93.3%)
 KIR2DS1248 (39.9%)35 (43.8%)39 (48.8%)36 (40.4%)
 KIR2DS2373 (60.1%)46 (57.5%)50 (62.5%)53 (59.6%)
 KIR2DS3198 (31.9%)27 (33.8%)33 (41.3%)31 (35.2%)
 KIR2DS4589 (94.8%)78 (97.5%)76 (95.0%)83 (93.3%)
 KIR2DS5181 (29.1%)33 (41.3%)b30 (37.5%)21 (23.9%)
 KIR3DS1256 (41.2%)36 (45.0%)39 (48.8%)38 (43.2%)
KIR ligands
 C1528 (85.0%)64 (80.0%)59 (73.8%)c78 (87.6%)
 C2407 (65.5%)52 (65.0%)55 (68.8%)50 (56.2%)
 Bw4487 (78.4%)62 (77.5%)66 (82.5%)68 (76.4%)
 A3/A11199 (32.0%)21 (26.2%)28 (35.0%)28 (31.8%)
Licensing iKIR/ligand interactions
 KIR2DL1/C2398 (64.1%)51 (63.8%)50 (62.5%)50 (56.2%)
 KIR2DL2/C1308 (49.6%)33 (41.2%)37 (46.3%)45 (50.6%)
 KIR2DL3/C1475 (76.5%)61 (76.2%)48 (60.0%)d66 (77.5%)
 KIR3DL1/Bw4464 (74.7%)60 (75.0%)62 (77.5%)63 (70.8%)
  • Fisher exact test:

  • aControl vs. bladder, P = 0.01, Pc < 0.05, OR = 1.82.

  • bControl vs. melanoma, P = 0.014, Pc > 0.05, OR = 1.78.

  • cControl vs. bladder, P < 0.01, Pc < 0.05, OR = 0.49.

  • dControl vs. bladder, P < 0.01, Pc < 0.05, OR = 0.46.